Cathy Friedman — SPARQNOW

At-a-Glance

Serves as an Executive Venture Partner at GV, where she advises the life sciences portfolio.
Spent nearly 24 years with Morgan Stanley, holding executive positions including Managing Director, Head of West Coast Healthcare, and co-head of its biotechnology practice.
Served 15 years on the boards of public and private life sciences and technology companies, including Lyell Immunopharma, Altaba, Grail (acquired by Illumina), and Vividion Therapeutics (acquired by Bayer).
Holds a B.A. in economics from Harvard University and an M.B.A from The University of Virginia's Darden School of Business.

Biography

Cathy Friedman is an Executive Venture Partner at GV, where she is a senior member of the investing team and advises the life sciences portfolio. She brings nearly 40 years of experience spanning finance, technology, and healthcare. Her current board roles include Lyell Immunopharma and Altaba.

Friedman has extensive board experience, having spent 15 years on the boards of leading public and private life sciences and technology companies.